Zurcher Kantonalbank Zurich Cantonalbank Has $34.72 Million Holdings in Eli Lilly and Co (NYSE:LLY)

Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Eli Lilly and Co (NYSE:LLY) by 22.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 411,114 shares of the company’s stock after purchasing an additional 74,733 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Eli Lilly and were worth $34,723,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Airain ltd acquired a new position in shares of Eli Lilly and in the 2nd quarter valued at $567,000. Buckingham Asset Management LLC lifted its holdings in Eli Lilly and by 21.3% in the 2nd quarter. Buckingham Asset Management LLC now owns 3,232 shares of the company’s stock worth $266,000 after buying an additional 568 shares in the last quarter. BSW Wealth Partners lifted its holdings in Eli Lilly and by 0.6% in the 2nd quarter. BSW Wealth Partners now owns 4,774 shares of the company’s stock worth $393,000 after buying an additional 27 shares in the last quarter. Mirador Capital Partners LP lifted its holdings in Eli Lilly and by 5.3% in the 2nd quarter. Mirador Capital Partners LP now owns 12,280 shares of the company’s stock worth $1,011,000 after buying an additional 619 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. lifted its holdings in Eli Lilly and by 166.7% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 430,424 shares of the company’s stock worth $36,818,000 after buying an additional 269,038 shares in the last quarter. 76.20% of the stock is owned by institutional investors and hedge funds.

A number of brokerages have commented on LLY. BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the stock a “sell” rating in a report on Tuesday, December 5th. Credit Suisse Group reaffirmed a “hold” rating and set a $80.00 price objective on shares of Eli Lilly and in a research report on Friday, February 2nd. Leerink Swann boosted their price objective on shares of Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a research report on Monday, October 23rd. Argus upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and increased their price target for the stock from $85.52 to $115.00 in a research note on Friday, January 5th. Finally, Jefferies Group set a $100.00 price target on shares of Eli Lilly and and gave the stock a “buy” rating in a research note on Tuesday, January 16th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $92.02.

In other Eli Lilly and news, insider Donald A. Zakrowski sold 900 shares of the stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $81.09, for a total transaction of $72,981.00. Following the transaction, the insider now directly owns 4,130 shares in the company, valued at approximately $334,901.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Jeffrey N. Simmons sold 12,500 shares of the stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $86.46, for a total value of $1,080,750.00. Following the transaction, the senior vice president now owns 124,522 shares in the company, valued at $10,766,172.12. The disclosure for this sale can be found here. Insiders sold 259,610 shares of company stock valued at $22,727,406 in the last ninety days. 0.20% of the stock is currently owned by insiders.

Shares of Eli Lilly and Co (NYSE:LLY) traded up $0.74 during trading on Thursday, hitting $77.77. 1,519,141 shares of the stock were exchanged, compared to its average volume of 5,270,127. Eli Lilly and Co has a 52 week low of $73.69 and a 52 week high of $89.09. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. The company has a market capitalization of $84,820.00, a PE ratio of -386.15, a PEG ratio of 1.42 and a beta of 0.23.

Eli Lilly and (NYSE:LLY) last issued its earnings results on Wednesday, January 31st. The company reported $1.14 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.08 by $0.06. Eli Lilly and had a positive return on equity of 31.44% and a negative net margin of 0.89%. The firm had revenue of $6.16 billion during the quarter, compared to the consensus estimate of $5.93 billion. During the same quarter in the previous year, the firm earned $0.95 earnings per share. The business’s quarterly revenue was up 7.0% on a year-over-year basis. equities analysts anticipate that Eli Lilly and Co will post 4.88 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be paid a $0.5625 dividend. The ex-dividend date is Wednesday, February 14th. This represents a $2.25 annualized dividend and a dividend yield of 2.89%. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s dividend payout ratio is currently -1,040.00%.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Week Herald and is the sole property of of Week Herald. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://weekherald.com/2018/02/15/zurcher-kantonalbank-zurich-cantonalbank-buys-74733-shares-of-eli-lilly-and-co-lly.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply